Hiteshi K.C. Chauhan: Why Mechanical Valve Thrombosis Is a Systems Failure, Not Just an Anticoagulation Error
Hiteshi K.C. Chauhan, Consultant, Department of Cardiology at Fortis Healthcare, shared a post on LinkedIn:
“We’ve all experienced this incredible moment in our clinical practice.
- A thrombosed mechanical mitral valve.
- Low-dose, slow-infusion thrombolysis.
- And then – the leaflets move again.
The tragedy: In LMICs, we see this more often than we would want to.
Thank you, Rheumatic Heart Disease.
For young patients receiving a mechanical valve, lifelong anticoagulation becomes essential.
Yet a study of 552 patients with RHD and mechanical valves found that only 27% of INR measurements were therapeutic, while 61% were subtherapeutic.
By year seven, INR testing had fallen to less than once a year.
Valve thrombosis is – therefore – not simply an anticoagulation failure. It is a systems failure surrounding a lifelong therapy.
We know what works:
- Reliable INR testing
- Affordable, consistent access to medication
- Continuity of care
- Long-term follow-up
The real challenge is implementation.
How do we make what works accessible at scale?
Case of low-dose, slow-infusion thrombolysis courtesy of JAMA Cardiology.”
Stay updated with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian